SynthesisProstate cancer and prostatic diseases2016
A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.
Synthesis in Prostate cancer and prostatic diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Pooled it
- Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses.Arteriosclerosis, thrombosis, and vascular biology · 2020Pooled it
- Machine learning-based prediction of post-operative outcomes in robotic-assisted radical prostatectomy: a multi-variable analysis of 758 cases.Journal of robotic surgery · 2025Article
- Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer.Current oncology reports · 2024Review
- Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes.JAMA network open · 2022Article
- The Role of Cardioprotection in Cancer Therapy Cardiotoxicity:JACC. CardioOncology · 2022Review
- Effectiveness of GnRH Antagonists and Agonists in Patients with Hormone-Sensitive Prostate Cancer: A Retrospective Study.Applied bionics and biomechanics · 2022Article
- Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers.Research and reports in urology · 2022Review
- Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer.The world journal of men's health · 2021Review
- Addressing Cardiovascular Risk of Prostate Cancer Hormonal Therapy.JACC. CardioOncology · 2020Article
- CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY.Acta clinica Croatica · 2019Review
- Prostate cancer and prostatic diseases Best of China, 2018.Prostate cancer and prostatic diseases · 2019Article
- Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer.Current treatment options in cardiovascular medicine · 2017Review
- Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder.PloS one · 2017Article
- Androgen deprivation therapy and side effects: are GnRH antagonists safer?Asian journal of andrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAndrogen-deprivation therapy (ADT) is the standard treatment for advanced and recurrent prostate cancer but it has been shown to cause adverse effects on the cardiovascular system. Intermittent androgen deprivation has been studied as an alternative therapy. To conduct a meta-analysis comparing the incidence of cardiovascular events in patients with prostate cancer receiving intermittent (IADT) versus continuous ADT (CADT).
methodsWe searched Cochrane CENTRAL, PubMed/Medline, Embase, Web of Science, The National Cancer Institute Clinical Trials and The Clinical Trials Register of Trials Central, and Google Scholar from inception of each database through February 2016. References from published guidelines, reviews and other relevant articles were also considered. We selected randomized clinical trials comparing IADT versus CADT in patients with prostate cancer that reported data on cardiovascular events. Two reviewers performed the study selection, data abstraction and risk of bias assessment. We calculated risk ratios with the Mantel-Haenszel method, using random effect models. We assessed heterogeneity using I
resultsOut of 106 references, we included seven articles from six trials (4810 patients) published between 2009 and 2015. We observed no significant difference between intermittent versus continuous androgen deprivation with respect to cardiovascular events (risk ratio (RR): 0.95; confidence interval (CI) 95%=0.83-1.08; seven trials, 4810 patients) and thromboembolic events (RR: 1.05; CI 95%=0.85-1.30; three trials, 1816 patients). There was marginally significant difference with respect to cardiovascular-related mortality (RR: 0.85; CI 95%=0.71-1.00; five trials, 4170 patients).
conclusionsCompared with CADT, IADT shows no difference in terms of cardiovascular events and thromboembolic events. However, there was an association between lower cardiovascular-related mortality and intermittent androgen deprivation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.